MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$150.15
−1.44%Year over year
Reported trailing growth
- Revenue
- +4.2%
- EBITDA
- -44.6%
- EBIT
- -48.3%
- EPS
- -80.6%
- Free cash flow
- +9.1%
- Operating cash flow
- +7.7%
Forward estimates
Based on analyst estimates
- Revenue
- +2.3%
- EBITDA
- +159.2%
- EPS
- +584.6%
Three-year CAGR
- Revenue
- +3.1%
- EBITDA
- +9.9%
- EBIT
- +8.7%
- Net income
- +7.9%
- EPS
- +8.4%
- Free cash flow
- -5.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026